Professor | Jinxue He | Asia Growth Partners

Name	Jinxue He
Contact Information	jinxue_he@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Jinxue He

Contact Information

jinxue_he@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2007-09--2012-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences 2003-09--2007-07 Bachelor's: Shandong University
Work Experience	2019-10~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher 2016-10~2019-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher 2016-02~2016-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher 2012-09~2016-01 - Weill Cornell Medicine - Postdoc

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2007-09--2012-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2003-09--2007-07 Bachelor's: Shandong University

Work Experience

2019-10~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2016-10~2019-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2016-02~2016-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
2012-09~2016-01 - Weill Cornell Medicine - Postdoc

Areas of Focus	Anti-tumor drug development and mechanism research DNA damage repair pathway and nuclear protein intervention research Development of new drugs targeting the ubiquitin-proteasome pathway
Publications	Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, Jinxue He, 2024 YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, Jinxue He, 2023 Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, Jinxue He, 2023 Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, Jinxue He, 2023 SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, Jinxue He, 2022 Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, Jinxue He, 2022 Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, Jinxue He, 2021 Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, Jinxue He, 2021 Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, Jinxue He, 2021 Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, Jinxue He, 2020 Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, Jinxue He, 2019 Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, Jinxue He, 2018 Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, Jinxue He, 2017 Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, Jinxue He, 2017 Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, Jinxue He, 2017 PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, Jinxue He, 2016 PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, Jinxue He, 2015

Areas of Focus

Anti-tumor drug development and mechanism research
DNA damage repair pathway and nuclear protein intervention research
Development of new drugs targeting the ubiquitin-proteasome pathway

Publications

Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, Jinxue He, 2024
YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, Jinxue He, 2023
Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, Jinxue He, 2023
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, Jinxue He, 2023
SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, Jinxue He, 2022
Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, Jinxue He, 2022
Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, Jinxue He, 2021
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, Jinxue He, 2021
Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, Jinxue He, 2021
Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, Jinxue He, 2020
Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, Jinxue He, 2019
Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, Jinxue He, 2018
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, Jinxue He, 2017
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, Jinxue He, 2017
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, Jinxue He, 2017
PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, Jinxue He, 2016
PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, Jinxue He, 2015

Anti-Tumor Drug Development Mechanism Research Dna Damage Repair Pathway Nuclear Protein Intervention Ubiquitin Proteasome New Drugs

Yi Li - University of Chinese Academy of Sciences

Shi-Lin Xu - University of Chinese Academy of Sciences

Jianying Huang - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us